Edition:
United States

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

1.32USD
23 Feb 2018
Change (% chg)

$0.11 (+9.09%)
Prev Close
$1.21
Open
$1.20
Day's High
$1.32
Day's Low
$1.18
Volume
27,363
Avg. Vol
62,695
52-wk High
$7.26
52-wk Low
$0.80

Chart for

About

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery... (more)

Overall

Beta: 8.14
Market Cap(Mil.): $19.84
Shares Outstanding(Mil.): 15.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-FDA Declines To Approve Aradigm's Drug Linhaliq

* ARADIGM RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR LINHALIQ NDA

Jan 29 2018

BUZZ-Aradigm Corp: Ladenburg Thalmann cuts rating to 'neutral'

** Drug developer's shares plunge 42.7 pct to $1.96 premarket - top pct loser among all U.S.-listed stocks

Jan 12 2018

BRIEF-Aradigm - FDA Advisory Committee Did Not Recommend Approval For Linhaliq

* ARADIGM REPORTS RESULTS OF FDA ADVISORY COMMITTEE MEETING ON LINHALIQ‍​

Jan 11 2018

BRIEF-Boxer Capital Reports 5.9 Pct Passive Stake In Aradigm Corp As Of Nov 30

* BOXER CAPITAL LLC REPORTS 5.9 PERCENT PASSIVE STAKE IN ARADIGM CORP AS OF NOVEMBER 30 - SEC FILING Source text: (http://bit.ly/2BDnINX) Further company coverage:

Dec 11 2017

BRIEF-Aradigm Announces FDA Advisory Committee Meeting For Linhaliq

* ARADIGM ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR LINHALIQ

Dec 01 2017

BRIEF-Aradigm Corp files for common stock offering of up to $20 mln

* Aradigm Corp files for common stock offering of up to $20 million - SEC filing‍​ Source text: (http://bit.ly/2lOJdUD) Further company coverage:

Nov 03 2017

BRIEF-Aradigm Q3 loss per share $0.26

* Aradigm corp - qtrly ‍rev $2.7 million versus $50,000​ Source text for Eikon: Further company coverage:

Nov 02 2017

Earnings vs. Estimates